Inventor · disambiguated record
Wojtek Auerbach
Also filed as: AUERBACH WOJTEK
34 granted patents·15 pending applications·1,228 citations·filing 2003–2024
98Inventor score
Top patents by PatentIndex Score
49 records- 0199US9546384B2Methods and compositions for the targeted modification of a mouse genomeREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·31 cites·26 claims
- 0299US9228208B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2014·Granted Jan 5, 2016·79 cites·24 claims
- 0398US10385359B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2017·Granted Aug 20, 2019·29 cites·39 claims
- 0498US10329582B2Genetic modification of ratsREGENERON PHARMA·Filed 2016·Granted Jun 25, 2019·25 cites·37 claims
- 0598US10208317B2Methods and compositions for the targeted modification of a mouse embryonic stem cell genomeREGENERON PHARMA·Filed 2016·Granted Feb 19, 2019·15 cites·61 claims
- 0698US7659442B2Method for making homozygous genetic modificationsREGENERON PHARMA·Filed 2007·Granted Feb 9, 2010·239 cites·18 claims
- 0798US7576259B2Method for making genetic modificationsREGENERON PHARMA·Filed 2007·Granted Aug 18, 2009·236 cites·18 claims
- 0898US7294754B2Method for generating an animal homozygous for a genetic modificationREGENERON PHARMA·Filed 2005·Granted Nov 13, 2007·445 cites·15 claims
- 0997US9730434B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2016·Granted Aug 15, 2017·11 cites·27 claims
- 1096US10301646B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2017·Granted May 28, 2019·12 cites·28 claims
- 1196US10039269B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2017·Granted Aug 7, 2018·10 cites·21 claims
- 1295US10711280B2Methods and compositions for the targeted modification of a mouse ES cell genomeREGENERON PHARMA·Filed 2018·Granted Jul 14, 2020·5 cites·69 claims
- 1395US9414575B2Methods and compositions for generating a mouseREGENERON PHARMA·Filed 2014·Granted Aug 16, 2016·12 cites·25 claims
- 1494US9834786B2Nuclease-mediated targeting with large targeting vectorsREGENERON PHARMA·Filed 2013·Granted Dec 5, 2017·13 cites·34 claims
- 1593US10975390B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2019·Granted Apr 13, 2021·4 cites·46 claims
- 1691US10457960B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2015·Granted Oct 29, 2019·5 cites·53 claims
- 1791US10106820B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2015·Granted Oct 23, 2018·6 cites·43 claims
- 1891US9902971B2Methods for producing a mouse XY embryonic (ES) cell line capable of producing a fertile XY female mouse in an F0 generationREGENERON PHARMA·Filed 2015·Granted Feb 27, 2018·5 cites·41 claims
- 1991US8816150B2Conditioned culture mediaPOUEYMIROU WILLIAM·Filed 2007·Granted Aug 26, 2014·14 cites·19 claims
- 2090US10793874B2Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2018·Granted Oct 6, 2020·4 cites·13 claims
- 2189US9655351B2Production of fertile XY female animals from XY ES cellsREGENERON PHARMA·Filed 2016·Granted May 23, 2017·3 cites·42 claims
- 2289US9398762B2Production of fertile XY female animals from XY ES cellsREGENERON PHARMA·Filed 2014·Granted Jul 26, 2016·7 cites·21 claims
- 2389US2024052365A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 2488US10894965B2Genetic modification of ratsREGENERON PHARMA·Filed 2019·Granted Jan 19, 2021·2 cites·39 claims
- 2588US9149026B2Production of fertile XY animals from XY ES cellsAUERBACH WOJTEK·Filed 2011·Granted Oct 6, 2015·8 cites·9 claims
- 2687US9885058B2Production of fertile XY female mice from XY mouse ES cellsREGENERON PHARMA·Filed 2017·Granted Feb 6, 2018·2 cites·26 claims
- 2786US2024352489A1Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2885US10294494B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2017·Granted May 21, 2019·2 cites·43 claims
- 2982US12060571B2Methods and compositions for modifying a targeted locusREGENERON PHARMA·Filed 2019·Granted Aug 13, 2024·1 cites·49 claims
- 3080US2023332185A1Methods and compositions for targeted genetic modification using paired guide rnasREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3179US11697828B2Methods and compositions for targeted genetic modification using paired guide RNAsREGENERON PHARMA·Filed 2019·Granted Jul 11, 2023·1 cites·33 claims
- 3278US12037596B2Targeted modification of rat genomeREGENERON PHARMA·Filed 2021·Granted Jul 16, 2024·0 cites·5 claims
- 3376US12065661B2Genetic modification of ratsREGENERON PHARMA·Filed 2020·Granted Aug 20, 2024·0 cites·21 claims
- 3476US11820997B2Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2020·Granted Nov 21, 2023·0 cites·73 claims
- 3575US10428310B2Methods and compositions for generating or maintaining pluripotent cellsREGENERON PHARMA·Filed 2015·Granted Oct 1, 2019·1 cites·23 claims
- 3671US10893666B2Production of fertile XY female animals by silencing of genes on the Y chromosomeREGENERON PHARMA·Filed 2016·Granted Jan 19, 2021·1 cites·26 claims
- 3770US2021024953A1Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 3868US2014310828A1Targeted modification of rat genomeREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 3966US12041918B2Production of fertile XY female animals by silencing of genes on the Y chromosomeREGENERON PHARMA·Filed 2020·Granted Jul 23, 2024·0 cites·18 claims
- 4063US2016060657A1Methods and compositions for the targeted modification of a genomeREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 4162US2009271884A1ES Cell-Derived Mice From Diploid Host Embryo InjectionREGENERON PHARMA·Filed 2009·Application pending·0 cites
- 4262US2014309487A1Targeted modification of rat genomeREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4362US2016108360A1Genetic modification of ratsREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 4461US2019382730A1Methods and compositions for generating or maintaining pluripotent cellsREGENERON PHARMA·Filed 2019·Application pending·0 cites
- 4561US2014235933A1Genetic modification of ratsREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 4658US2016046960A1Methods and compositions for targeted genetic modifications and methods of useREGENERON PHARMA·Filed 2015·Application pending·0 cites
- 4752US2005101017A1Method of improving gene targeting using a ubiquitin promoterFiled 2003·Application pending·0 cites
- 4851US2016316728A1ES Cell-Derived Mice From Diploid Host Embryo InjectionREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 4949US2006064770A1Methods for identifying a cell or an embryo carrying a Y chromosomeFRENDEWEY DAVID·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Wojtek Auerbach files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →